Daewoong has added a line-up of osteoporosis treatments PO

Introduction of Raloxifen PO with Zoledronic Acid injection added to major item

Daewoong's Evimax 45mg was approved on July 29.

 

It is generic for Raloxifene HCl 45mg.

 

The original for Raloxifene HCl is Evista from Alvogen Korea.

 

Evista contains Raloxifene HCl 60 mg.

 

Raloxifene HCl 45mg was first developed by Yuhan.

 

In September 2019, Yuhan was granted 'Raboni 45mg', a product containing Raloxifene HCl 45mg.

 

The company explains that safety has been increased by lowering the content of Raloxifene HCl by improving its bioavailability.

 

Daewoong's approved product is also manufactured and supplied by Yuhan.

 

In June, Daewoong was previously granted "Evimax D," a combination of Raloxifene HCl 45mg and a concentrated vitamin D powder.

 

This is also an item produced by Yuhan.

 

As a result, Daewoong will have three Raloxifene preparations, including Daewoong Raloxifene HCl 60mg, which was approved in March last year.

 

Daewoong has been selling Daewoong Zoledronic Acid as a treatment for osteoporosis and Ricen Plus as an oral medicine.

 

The performance is not bad either.

 

Based on IQVIA last year, Daewoong Zoledronic Acid recorded ₩11.2 billion and Ricen Plus, which is a combination of Risedronic acid and Cholesterol, recorded ₩1.5 billion.

 

In terms of sales, oral products are less competitive than injection products.

 

For this reason, Daewoong needed the latest treatment for oral osteoporosis.

 

It is believed that the company introduced Raloxifene HCl 45mg developed by its competitor Yuhan first.

 

In the past, Daewoong sold original osteoporosis drugs such as Fosamax Plus D and had the largest share in the oral market.

 

However, due to the termination of the contract for MSD's Fosamax, it suffered from losing its main items.

 

Zoldronic Acid, which had little sales at the time, was successful by co-promoting with Sandoz.

 

Since then, the Zoldronic Acid injection has been manufactured by Daewoong by purchasing copyrights.

 

Considering Daewoong's business competitiveness in the osteoporosis treatment market, the introduction of Raloxifene HCl 45mg is also likely to be successful.

 

Attention is focusing on how much sales Daewoong will make in the osteoporosis treatment oral market through the launch of a new product.